A Phase 2 interventional study of BMS-986036 and Placebo in Liver Fibrosis, Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis, sponsored by Bristol-Myers Squibb. Completed at 89 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-09-09.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 231 studies in Liver Cirrhosis with a site in United States — 45 open to participants now, 63 under way, 3 of them phase 3. Liver Cirrhosis · United States.
Among the 231 studies in Liver Cirrhosis with a site in United States, this one is the 39th largest by enrollment of the 166 interventional ones that give a count, is one of 21 that started in 2018, is one of 58 in phase 2, and was the 91st registered.
1,302 studies on the registry are indexed under Liver Cirrhosis; 340 are open to participants now.
Browse Liver Cirrhosis studies →45 of the 231 studies in Liver Cirrhosis with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
Regeneron Pharmaceuticals · Sites in United States, Puerto Rico, United Kingdom
Ages 18–75
AstraZeneca · Sites in United States, Puerto Rico
Ages 18+
Duke University · Sites in United States
Ages 18+
Boehringer Ingelheim · Sites in United States, Canada
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
231 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 31 · Phase 2 63 · Phase 3 15 · Phase 4 14
First in 1993; this study’s year is marked. 21 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 197 is above the median of 78 across 742 interventional studies indexed under Liver Cirrhosis.
Median enrollment 55 across the 166 interventional studies, 109 across the 63 observational. Of the 150 that completed or were terminated, 63 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
85 of 231 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Bristol-Myers Squibb has 6 studies filed under Liver Cirrhosis — fewer than ten, so there is no comparison to draw.
24 of the studies in Liver Cirrhosis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05500222Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) | 2026-12 |
| NCT04592744University of California, Los AngelesAngiotensin 2 for AKI After OLT | 2026-12 |
| NCT03973372University of Texas Southwestern Medical CenterALTA TIPS: A 5-year Longitudinal Observational Study of Patients Undergoing TIPS Placement | 2026-12 |
| NCT05998330Massachusetts General HospitalLiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease | 2026-12-01 |
| NCT04820036Brigham and Women's HospitalA Physiologic Analysis of Endoscopic Sleeve Gastroplasty (ESG) | 2026-12-24 |
Add all 24 to your calendar (.ics) → With an account.
Among the 231 studies in Liver Cirrhosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a study of experimental medication BMS-986036 given to adults with Nonalcoholic Steatohepatitis (NASH; the buildup of fat and inflammation in the liver that is not caused by alcohol) and stage 3 liver fibrosis (severe fibrosis).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administered by subcutaneous injection.
Drug: BMS-986036
Administered by subcutaneous injection.
Drug: BMS-986036
Administered by subcutaneous injection.
Drug: BMS-986036
Administered by subcutaneous injection.
Other: Placebo
Specified dose on specified days.
Also known as: Pegbelfermin
Specified dose on specified days.
The Percentage of Participants With Improvement in Fibrosis or Nonalcoholic Steatohepatitis (NASH) at Week 24
The percentage of participants who achieved a ≥1-stage improvement in fibrosis without worsening of NASH or NASH improvement with no worsening of fibrosis at week 24 in liver biopsy. Improvement in fibrosis is defined by the NASH Clinical Research Network (CRN) Fibrosis Score. Improvement in NASH is defined by a ≥2-stage decrease in the nonalcoholic fatty liver disease activity score (NAS). Worsening of NASH is defined as an increase of the nonalcoholic fatty liver disease (NAFLD) Activity Score (NAS) by ≥1 point. Worsening of fibrosis is defined as an increase of fibrosis by ≥1 point as determined by the NASH CRN Fibrosis Score. NASH CRN Fibrosis is staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).
Time frame: From first dose to 24 weeks after first dose
The Percentage of Participants Who Achieved an Improvement in Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) Fibrosis Score at Week 24
An improvement in fibrosis is defined as a decrease of ≥ 1-stage in the NASH CRN Fibrosis Score at week 24 in liver biopsy. NASH CRN Fibrosis is staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).
Time frame: From first dose to 24 weeks after first dose
The Percentage of Participants Who Achieve a ≥ 1-Stage Improvement in Ishak Fibrosis Score at Week 24
An improvement in Ishak fibrosis is defined as a decrease of fibrosis by ≥ 1-stage in the Ishak fibrosis score at week 24 in liver biopsy. ISHAKs uses a 0-6 scale: 1: centrilobular pericellular fibrosis, 2: centrilobular and periportal fibrosis, 3: bridging fibrosis (few bridges), 4: bridging fibrosis (many bridges), 5: early or incomplete cirrhosis, 6: established or advanced cirrhosis.
Time frame: From first dose to 24 weeks after first dose
The Percentage of Participants With Any Improvement in Collagen Proportionate Area (CPA) at Week 24
An improvement in CPA is defined as any decrease in CPA at week 24 in liver biopsy.
Time frame: From first dose to 24 weeks after first dose
The Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis at Week 24
The percentage of participants with NASH resolution without worsening of fibrosis at week 24 in liver biopsy. NASH resolution defined by the nonalcoholic fatty liver disease activity score (NAS) component of ballooning = 0 and inflammation = 0-1. Worsening of fibrosis is defined as an increase of fibrosis by ≥ 1-stage in the NASH Clinical Research Network (CRN) Fibrosis Score. Ballooning = 0 (none) inflammation = 0 (none) - 1 (Grade \<2). NASH CRN Fibrosis is staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).
Time frame: From first dose to 24 weeks after first dose
The Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution at Week 24
NASH resolution defined by the nonalcoholic fatty liver disease activity score (NAS) component of ballooning = 0 and inflammation = 0-1 at week 24 in liver biopsy. Ballooning = 0 (none) inflammation = 0 (none) - 1 (Grade \<2).
Time frame: From first dose to 24 weeks after first dose
The Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Improvement Without Worsening of Fibrosis at Week 24
The percentage of participants with NASH improvement without worsening of fibrosis at week 24 in liver biopsy. NASH improvement defined as a reduction of nonalcoholic fatty liver disease activity score (NAS) by ≥2 points with contribution from \>1 NAS component. Worsening of fibrosis is defined as an increase of ≥1-point in the NASH Clinical Research Network (CRN) Fibrosis Score. NASH CRN Fibrosis is staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).
Time frame: From first dose to 24 weeks after first dose
The Percentage of Participants Who Achieve a ≥ 1-Stage Improvement in Fibrosis Without Worsening of Nonalcoholic Steatohepatitis (NASH) at Week 24
An improvement in fibrosis is defined as a decrease of fibrosis by ≥1-stage in the NASH Clinical Research Network (CRN) Fibrosis Score at week 24 in liver biopsy. Worsening of NASH is defined as an increase of the nonalcoholic fatty liver disease activity score (NAS) by ≥ 1-stage. NASH CRN Fibrosis is staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).
Time frame: From first dose to 24 weeks after first dose
The Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Improvement at Week 24
The percentage of participants with NASH improvement at week 24 in liver biopsy. NASH improvement is defined as a reduction of nonalcoholic fatty liver disease activity score (NAS) by ≥ 2 points with contribution from \> 1 NAS component. The NASH CRN system assesses liver biopsies for degree of steatosis (0-3), lobular inflammation (0-3), hepatocellular ballooning (0-2), and fibrosis (0-4). The 3 categories are added together in an unweighted fashion to determine the NAS, which ranges from 0 to 8.
Time frame: From first dose to 24 weeks after first dose
The Percentage of Participants With Progression to Cirrhosis at Week 24
Progression to cirrhosis is defined by the nonalcoholic steatohepatitis clinical research network (NASH CRN) Fibrosis Stage 4 at Week 24 in liver biopsy. NASH CRN Fibrosis is staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).
Time frame: From first dose to 24 weeks after first dose
| Milestone | BMS-986036 10 mg | BMS-986036 20 mg | BMS-986036 40 mg | Placebo |
|---|---|---|---|---|
| Started | 49 | 50 | 49 | 49 |
| Completed | 41 | 39 | 41 | 39 |
| Not completed | 8 | 11 | 8 | 10 |
| Withdrew: Lost to follow-up | 4 | 1 | 4 | 3 |
| Withdrew: Death | 1 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 2 | 0 | 2 |
| Withdrew: Withdrawal by subject | 3 | 7 | 4 | 3 |
| Withdrew: Other reasons | 0 | 1 | 0 | 1 |
The percentage of participants who achieved a ≥1-stage improvement in fibrosis without worsening of NASH or NASH improvement with no worsening of fibrosis at week 24 in liver biopsy. Improvement in fibrosis is defined by the NASH Clinical Research Network (CRN) Fibrosis Score. Improvement in NASH is defined by a ≥2-stage decrease in the nonalcoholic fatty liver disease activity score (NAS). Worsening of NASH is defined as an increase of the nonalcoholic fatty liver disease (NAFLD) Activity Score (NAS) by ≥1 point. Worsening of fibrosis is defined as an increase of fibrosis by ≥1 point as determined by the NASH CRN Fibrosis Score. NASH CRN Fibrosis is staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).
| Percentage of Participants | BMS-986036 10 mg | BMS-986036 20 mg | BMS-986036 40 mg | Placebo |
|---|---|---|---|---|
| The Percentage of Participants With Improvement in Fibrosis or Nonalcoholic Steatohepatitis (NASH) at Week 24 | 30.6 (0.88 to 8.52) | 24.0 (0.61 to 6.27) | 26.5 (0.71 to 7.10) | 14.3 (NA to NA) |
An improvement in fibrosis is defined as a decrease of ≥ 1-stage in the NASH CRN Fibrosis Score at week 24 in liver biopsy. NASH CRN Fibrosis is staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).
| Percentage of Participants | BMS-986036 10 mg | BMS-986036 20 mg | BMS-986036 40 mg | Placebo |
|---|---|---|---|---|
| The Percentage of Participants Who Achieved an Improvement in Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) Fibrosis Score at Week 24 | 16.3 | 14.0 | 20.4 | 8.2 |
An improvement in Ishak fibrosis is defined as a decrease of fibrosis by ≥ 1-stage in the Ishak fibrosis score at week 24 in liver biopsy. ISHAKs uses a 0-6 scale: 1: centrilobular pericellular fibrosis, 2: centrilobular and periportal fibrosis, 3: bridging fibrosis (few bridges), 4: bridging fibrosis (many bridges), 5: early or incomplete cirrhosis, 6: established or advanced cirrhosis.
| Percentage of Participants | BMS-986036 10 mg | BMS-986036 20 mg | BMS-986036 40 mg | Placebo |
|---|---|---|---|---|
| The Percentage of Participants Who Achieve a ≥ 1-Stage Improvement in Ishak Fibrosis Score at Week 24 | 22.4 | 16.0 | 26.5 | 12.2 |
An improvement in CPA is defined as any decrease in CPA at week 24 in liver biopsy.
| Percentage of Participants | BMS-986036 10 mg | BMS-986036 20 mg | BMS-986036 40 mg | Placebo |
|---|---|---|---|---|
| The Percentage of Participants With Any Improvement in Collagen Proportionate Area (CPA) at Week 24 | 42.9 | 53.5 | 55.8 | 65.9 |
The percentage of participants with NASH resolution without worsening of fibrosis at week 24 in liver biopsy. NASH resolution defined by the nonalcoholic fatty liver disease activity score (NAS) component of ballooning = 0 and inflammation = 0-1. Worsening of fibrosis is defined as an increase of fibrosis by ≥ 1-stage in the NASH Clinical Research Network (CRN) Fibrosis Score. Ballooning = 0 (none) inflammation = 0 (none) - 1 (Grade \<2). NASH CRN Fibrosis is staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).
| Percentage Participants | BMS-986036 10 mg | BMS-986036 20 mg | BMS-986036 40 mg | Placebo |
|---|---|---|---|---|
| The Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis at Week 24 | 8.2 | 4.0 | 2.0 | 6.1 |
NASH resolution defined by the nonalcoholic fatty liver disease activity score (NAS) component of ballooning = 0 and inflammation = 0-1 at week 24 in liver biopsy. Ballooning = 0 (none) inflammation = 0 (none) - 1 (Grade \<2).
| Percentage of Participants | BMS-986036 10 mg | BMS-986036 20 mg | BMS-986036 40 mg | Placebo |
|---|---|---|---|---|
| The Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution at Week 24 | 8.2 | 4.0 | 2.0 | 6.1 |
The percentage of participants with NASH improvement without worsening of fibrosis at week 24 in liver biopsy. NASH improvement defined as a reduction of nonalcoholic fatty liver disease activity score (NAS) by ≥2 points with contribution from \>1 NAS component. Worsening of fibrosis is defined as an increase of ≥1-point in the NASH Clinical Research Network (CRN) Fibrosis Score. NASH CRN Fibrosis is staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).
| Percentage of Participants | BMS-986036 10 mg | BMS-986036 20 mg | BMS-986036 40 mg | Placebo |
|---|---|---|---|---|
| The Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Improvement Without Worsening of Fibrosis at Week 24 | 22.4 | 14.0 | 16.3 | 10.2 |
An improvement in fibrosis is defined as a decrease of fibrosis by ≥1-stage in the NASH Clinical Research Network (CRN) Fibrosis Score at week 24 in liver biopsy. Worsening of NASH is defined as an increase of the nonalcoholic fatty liver disease activity score (NAS) by ≥ 1-stage. NASH CRN Fibrosis is staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).
| Percentage of Participants | BMS-986036 10 mg | BMS-986036 20 mg | BMS-986036 40 mg | Placebo |
|---|---|---|---|---|
| The Percentage of Participants Who Achieve a ≥ 1-Stage Improvement in Fibrosis Without Worsening of Nonalcoholic Steatohepatitis (NASH) at Week 24 | 16.3 | 14.0 | 16.3 | 8.2 |
The percentage of participants with NASH improvement at week 24 in liver biopsy. NASH improvement is defined as a reduction of nonalcoholic fatty liver disease activity score (NAS) by ≥ 2 points with contribution from \> 1 NAS component. The NASH CRN system assesses liver biopsies for degree of steatosis (0-3), lobular inflammation (0-3), hepatocellular ballooning (0-2), and fibrosis (0-4). The 3 categories are added together in an unweighted fashion to determine the NAS, which ranges from 0 to 8.
| Percentage of Participants | BMS-986036 10 mg | BMS-986036 20 mg | BMS-986036 40 mg | Placebo |
|---|---|---|---|---|
| The Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Improvement at Week 24 | 24.5 | 18.0 | 16.3 | 10.2 |
Progression to cirrhosis is defined by the nonalcoholic steatohepatitis clinical research network (NASH CRN) Fibrosis Stage 4 at Week 24 in liver biopsy. NASH CRN Fibrosis is staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).
| Percentage of Participants | BMS-986036 10 mg | BMS-986036 20 mg | BMS-986036 40 mg | Placebo |
|---|---|---|---|---|
| The Percentage of Participants With Progression to Cirrhosis at Week 24 | 30.6 | 22.0 | 28.6 | 20.4 |
Collected over All-cause mortality was assessed from first dose to study completion (up to approximately 35 months). SAEs and Other AEs were assessed from first dose to 30 days following last dose (up to approximately 52 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BMS-986036 10 mg | 1/49 (2%) | 3/49 (6.1%) | 36/49 (73.5%) |
| BMS-986036 20 mg | 0/50 (0%) | 7/50 (14%) | 38/50 (76%) |
| BMS-986036 40 mg | 0/49 (0%) | 6/49 (12.2%) | 39/49 (79.6%) |
| BMS-986036 Placebo | 1/49 (2%) | 9/49 (18.4%) | 33/49 (67.3%) |
| Event | BMS-986036 10 mg | BMS-986036 20 mg | BMS-986036 40 mg | BMS-986036 Placebo |
|---|---|---|---|---|
| Non-cardiac chest painGeneral disorders | 0/49 | 1/50 | 0/49 | 2/49 |
| Coronary artery diseaseCardiac disorders | 0/49 | 0/50 | 0/49 | 1/49 |
| Coronary artery occlusionCardiac disorders | 0/49 | 0/50 | 1/49 | 0/49 |
| Abdominal pain upperGastrointestinal disorders | 0/49 | 0/50 | 1/49 | 0/49 |
| Epiploic appendagitisGastrointestinal disorders | 1/49 | 0/50 | 0/49 | 0/49 |
| CholecystitisHepatobiliary disorders | 0/49 | 1/50 | 1/49 | 0/49 |
| COVID-19 pneumoniaInfections and infestations | 0/49 | 1/50 | 1/49 | 0/49 |
| Post procedural infectionInfections and infestations | 0/49 | 0/50 | 0/49 | 1/49 |
| SepsisInfections and infestations | 0/49 | 0/50 | 0/49 | 1/49 |
| Foot fractureInjury, poisoning and procedural complications | 0/49 | 0/50 | 0/49 | 1/49 |
| Event | BMS-986036 10 mg | BMS-986036 20 mg | BMS-986036 40 mg | BMS-986036 Placebo |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 13/49 | 11/50 | 7/49 | 8/49 |
| DiarrhoeaGastrointestinal disorders | 11/49 | 10/50 | 11/49 | 6/49 |
| Injection site erythemaGeneral disorders | 2/49 | 3/50 | 7/49 | 0/49 |
| FatigueGeneral disorders | 3/49 | 7/50 | 1/49 | 4/49 |
| Abdominal pain upperGastrointestinal disorders | 6/49 | 2/50 | 3/49 | 2/49 |
| Upper respiratory tract infectionInfections and infestations | 5/49 | 6/50 | 6/49 | 6/49 |
| Urinary tract infectionInfections and infestations | 3/49 | 2/50 | 4/49 | 6/49 |
| HeadacheNervous system disorders | 5/49 | 4/50 | 2/49 | 6/49 |
| RashSkin and subcutaneous tissue disorders | 1/49 | 2/50 | 6/49 | 1/49 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/49 | 6/50 | 2/49 | 4/49 |
| Age, Continuous(Years) | BMS-986036 10 mg | BMS-986036 20 mg | BMS-986036 40 mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 56.4 ± 9.57 | 56.3 ± 10.08 | 57.4 ± 10.50 | 57.5 ± 8.02 | 56.9 ± 9.53 |
| Sex: Female, Male(Participants) | BMS-986036 10 mg | BMS-986036 20 mg | BMS-986036 40 mg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 29 | 27 | 31 | 29 | 116 |
| Male | 20 | 23 | 18 | 20 | 81 |
| Ethnicity (NIH/OMB)(Participants) | BMS-986036 10 mg | BMS-986036 20 mg | BMS-986036 40 mg | Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 14 | 17 | 15 | 15 | 61 |
| Not Hispanic or Latino | 34 | 32 | 34 | 33 | 133 |
| Unknown or Not Reported | 1 | 1 | 0 | 1 | 3 |
| Race (NIH/OMB)(Participants) | BMS-986036 10 mg | BMS-986036 20 mg | BMS-986036 40 mg | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 3 | 7 | 4 | 4 | 18 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 1 | 2 |
| White | 43 | 42 | 42 | 41 | 168 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 1 | 2 | 3 | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2018 to primary completion in Sep 2020, 26 months.
Results were first posted in Sep 2022, 1 year 11 months after primary completion. A results delay was requested in Jul 2021.
Of 28 industry-sponsored phase 2 interventional studies under Liver Cirrhosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 27. This study's 26 months is close to that.
Counting every sponsor, half of 55 studies reached it within 27 months; a quarter within 19 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pegbelfermin